Literature DB >> 35880998

Evaluating the power of the causal impact method in observational studies of HCV treatment as prevention.

Pantelis Samartsidis1, Natasha N Martin2, Victor De Gruttola3, Frank De Vocht4, Sharon Hutchinson5,6, Judith J Lok7, Amy Puenpatom8, Rui Wang9,10, Matthew Hickman4, Daniela De Angelis1.   

Abstract

Objectives: The causal impact method (CIM) was recently introduced for evaluation of binary interventions using observational time-series data. The CIM is appealing for practical use as it can adjust for temporal trends and account for the potential of unobserved confounding. However, the method was initially developed for applications involving large datasets and hence its potential in small epidemiological studies is still unclear. Further, the effects that measurement error can have on the performance of the CIM have not been studied yet. The objective of this work is to investigate both of these open problems.
Methods: Motivated by an existing dataset of HCV surveillance in the UK, we perform simulation experiments to investigate the effect of several characteristics of the data on the performance of the CIM. Further, we quantify the effects of measurement error on the performance of the CIM and extend the method to deal with this problem.
Results: We identify multiple characteristics of the data that affect the ability of the CIM to detect an intervention effect including the length of time-series, the variability of the outcome and the degree of correlation between the outcome of the treated unit and the outcomes of controls. We show that measurement error can introduce biases in the estimated intervention effects and heavily reduce the power of the CIM. Using an extended CIM, some of these adverse effects can be mitigated. Conclusions: The CIM can provide satisfactory power in public health interventions. The method may provide misleading results in the presence of measurement error.
© 2021 Walter de Gruyter GmbH, Berlin/Boston.

Entities:  

Keywords:  HCV; causal impact; causal inference; measurement error

Year:  2021        PMID: 35880998      PMCID: PMC9204771          DOI: 10.1515/scid-2020-0005

Source DB:  PubMed          Journal:  Stat Commun Infect Dis        ISSN: 1948-4690


  31 in total

1.  Optimal targeting of Hepatitis C virus treatment among injecting drug users to those not enrolled in methadone maintenance programs.

Authors:  Irmgard Zeiler; Trevor Langlands; John M Murray; Alison Ritter
Journal:  Drug Alcohol Depend       Date:  2010-04-28       Impact factor: 4.492

2.  Cost-effectiveness of hepatitis C virus antiviral treatment for injection drug user populations.

Authors:  Natasha K Martin; Peter Vickerman; Alec Miners; Graham R Foster; Sharon J Hutchinson; David J Goldberg; Matthew Hickman
Journal:  Hepatology       Date:  2011-12-06       Impact factor: 17.425

Review 3.  Addressing liver disease in the UK: a blueprint for attaining excellence in health care and reducing premature mortality from lifestyle issues of excess consumption of alcohol, obesity, and viral hepatitis.

Authors:  Roger Williams; Richard Aspinall; Mark Bellis; Ginette Camps-Walsh; Matthew Cramp; Anil Dhawan; James Ferguson; Dan Forton; Graham Foster; Ian Gilmore; Matthew Hickman; Mark Hudson; Deirdre Kelly; Andrew Langford; Martin Lombard; Louise Longworth; Natasha Martin; Kieran Moriarty; Philip Newsome; John O'Grady; Rachel Pryke; Harry Rutter; Stephen Ryder; Nick Sheron; Tom Smith
Journal:  Lancet       Date:  2014-11-29       Impact factor: 79.321

4.  Combination interventions to prevent HCV transmission among people who inject drugs: modeling the impact of antiviral treatment, needle and syringe programs, and opiate substitution therapy.

Authors:  Natasha K Martin; Matthew Hickman; Sharon J Hutchinson; David J Goldberg; Peter Vickerman
Journal:  Clin Infect Dis       Date:  2013-08       Impact factor: 9.079

5.  Prioritization of HCV treatment in the direct-acting antiviral era: An economic evaluation.

Authors:  Natasha K Martin; Peter Vickerman; Gregory J Dore; Jason Grebely; Alec Miners; John Cairns; Graham R Foster; Sharon J Hutchinson; David J Goldberg; Thomas C S Martin; Mary Ramsay; Matthew Hickman
Journal:  J Hepatol       Date:  2016-02-08       Impact factor: 25.083

6.  Interrupted time series regression for the evaluation of public health interventions: a tutorial.

Authors:  James Lopez Bernal; Steven Cummins; Antonio Gasparrini
Journal:  Int J Epidemiol       Date:  2017-02-01       Impact factor: 7.196

7.  Evaluating the population impact of hepatitis C direct acting antiviral treatment as prevention for people who inject drugs (EPIToPe) - a natural experiment (protocol).

Authors:  Matthew Hickman; John F Dillon; Lawrie Elliott; Daniela De Angelis; Peter Vickerman; Graham Foster; Peter Donnan; Ann Eriksen; Paul Flowers; David Goldberg; William Hollingworth; Samreen Ijaz; David Liddell; Sema Mandal; Natasha Martin; Lewis J Z Beer; Kate Drysdale; Hannah Fraser; Rachel Glass; Lesley Graham; Rory N Gunson; Emma Hamilton; Helen Harris; Magdalena Harris; Ross Harris; Ellen Heinsbroek; Vivian Hope; Jeremy Horwood; Sarah Karen Inglis; Hamish Innes; Athene Lane; Jade Meadows; Andrew McAuley; Chris Metcalfe; Stephanie Migchelsen; Alex Murray; Gareth Myring; Norah E Palmateer; Anne Presanis; Andrew Radley; Mary Ramsay; Pantelis Samartsidis; Ruth Simmons; Katy Sinka; Gabriele Vojt; Zoe Ward; David Whiteley; Alan Yeung; Sharon J Hutchinson
Journal:  BMJ Open       Date:  2019-09-24       Impact factor: 2.692

8.  Hepatitis C transmission and treatment in contact networks of people who inject drugs.

Authors:  David A Rolls; Rachel Sacks-Davis; Rebecca Jenkinson; Emma McBryde; Philippa Pattison; Garry Robins; Margaret Hellard
Journal:  PLoS One       Date:  2013-11-01       Impact factor: 3.240

9.  Monitoring the hepatitis C epidemic in England and evaluating intervention scale-up using routinely collected data.

Authors:  Ross J Harris; Helen E Harris; Sema Mandal; Mary Ramsay; Peter Vickerman; Matthew Hickman; Daniela De Angelis
Journal:  J Viral Hepat       Date:  2019-02-28       Impact factor: 3.728

10.  Hepatitis C virus treatment for prevention among people who inject drugs: Modeling treatment scale-up in the age of direct-acting antivirals.

Authors:  Natasha K Martin; Peter Vickerman; Jason Grebely; Margaret Hellard; Sharon J Hutchinson; Viviane D Lima; Graham R Foster; John F Dillon; David J Goldberg; Gregory J Dore; Matthew Hickman
Journal:  Hepatology       Date:  2013-08-26       Impact factor: 17.425

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.